Akari Therapeutics Plc (AKTX): Nasdaq/NYSE listing notice — Akari Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Akari Therapeutics Plc

Nasdaq notified Akari on Nov 24, 2025 that ADS closing bid price below $1.00 for 30 consecutive business days.
Company has 180 calendar days (until May 25, 2026) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured by May 25, 2026, Akari may be eligible for an additional 180-day period if other listing standards are met.
Failure to regain compliance could result in delisting of ADSs from Nasdaq Capital Market.
Akari may consider an ADS ratio change to address the bid price deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0001493152-25-025177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.